Brief: Alterity Therapeutics Granted US FDA Fast Track Designation For Lead Candidate To Treat Multiple System Atrophy
05/05/2025 12:46
May 5 (Reuters) - Alterity Therapeutics Ltd ATH.AX: ALTERITY THERAPEUTICS GRANTED U.S. FDA FAST TRACK DESIGNATION FOR ATH434 TO TREAT MULTIPLE SYSTEM ATROPHY Source text: ID:nGNX20Qrv1 Further company coverage: ATH.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alterity Therapeutics
See all newsBrief: Alterity Therapeutics Achieves Alignment With U.S. FDA On Pivotal Phase 3 Program For Ath434 In Multiple System Atrophy
Brief: Alterity Therapeutics Receives Positive FDA Feedback On Ath434 Phase 3 Program
Brief: Alterity Therapeutics Says Julian Barbaczy Appointed Non-Exec Chair
Brief: Alterity Therapeutics Raises A$20.0 Million In Strategic Placement
Brief: Alterity Therapeutics Ltd Raises A$20 Million In Capital